Accession Number:



Protective Monotherapy Against Lethal Ebola Virus Infection by a Potently Neutralizing Antibody

Corporate Author:

United States Army Medical Research Institute of Infectious Diseases Frederick United States

Report Date:



Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25-90. There is no licensed treatment or vaccine against the virus, underscoring needs for efficacious countermeasures. Here, we demonstrate that human survivors of Ebola virus disease maintain circulating antibodies against the Ebola virus surface glycoprotein for more than a decade after infection, and we isolated monoclonal antibodies mAb from one survivor of the 1995 Kikwit outbreak in the Democratic Republic of Congo. These mAbs bind and neutralize recent and previous outbreak strains of Ebola virus, and mediate antibody-dependent cell- mediated cytotoxicity in vitro. Administration of a single potently neutralizing antibody, mAb114, protected infected macaques from death and clinical illness when administered one day after lethal challenge. Treatment with a single human mAb suggests a simplified therapeutic strategy for human Ebola infection may be possible.

Descriptive Note:

Journal Article

Supplementary Note:

Science , 01, 01, 01 Jan 0001, 01 Jan 0001,




Distribution Statement:

Approved For Public Release;

File Size: